![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Pfizer Global Research and Development, Groton, Connecticut
Received September 9, 2005; accepted October 3, 2005.
| Abstract |
|---|
|
|
|---|
|
| Materials and Methods |
|---|
|
|
|---|
Dosing Protocol. The experiment was a crossover design in which five dogs received each of the following five treatments in random order: 1) L-768,673 + E-4031 + isoproterenol, 2) vehicle + E-4031 + isoproterenol, 3) L-768,673 + vehicle + isoproterenol, 4) vehicle + vehicle + isoproterenol, and 5) vehicle + vehicle + saline. Studies in individual animals were separated by at least 7 days to allow for washout of compounds. A timeline that illustrates the infusion of compounds is shown in Fig. 1.
L-768,673 was synthesized at Pfizer Central Research (Sandwich, Kent, UK), dissolved in 100% ethanol, and then suspended in Intralipid 20% fat emulsion (Baxter, Deerfield, IL). Final vehicle solution was 5% ethanol and 95% Intralipid. L-768,673 was administered at 100 µg of free base per kilogram as a constant infusion over 15 min. This dose was shown by Salata et al. (2004
) to achieve rate-dependent refractoriness associated with QTc prolongation in conscious dogs of about 10% and a plasma concentration of approximately 100 ng/ml.
E-4031 was synthesized at Pfizer Central Research and dissolved in saline. The clinically relevant free drug concentration of E-4031 to produce a 10 to 15% increase in QT prolongation is between 3 and 4 nM (Fujiki et al., 1994
). In this study, three ascending doses were administered as described previously and measured (Fossa et al., 2002
) to achieve clinically relevant concentrations of 0.6, 1.7, and 8.8 nM free drug. Infusion of E-4031 began 5 min after the end of the infusion of L-768,673 or vehicle.
±-Isoproterenol hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in saline. The experimental data were assessed separately during each period as before isoproterenol (A) and during isoproterenol (B) (Fig. 1). Four separate infusions of isoproterenol, 0.2 µg of free base per kilogram, were given over 1 min in each study: one infusion during period 1B and one infusion at 5 min of each maintenance dose of E-4031 or vehicle (periods 2B, 3B, and 4B). This dose of isoproterenol causes an increase heart rate of approximately 180 bpm over the 1-min infusion, followed by a gradual decrease in heart rate back to the preisoproterenol level within 10 min.
Review of Dynamic Beat-to-Beat Data. ECG waveforms were replayed on the Po-Ne-Mah system, and each cardiac cycle was reviewed for accurate detection of the beginning of the Q wave and the end of the T wave as described previously (Fossa et al., 2005
). All computer-generated validation marks were visually inspected. QT intervals that could not be measured due to motion artifact or electrical noise of the ECG were removed from the data set, and if necessary the QT interval was manually measured using a digital measure command on the Po-Ne-Mah system. Similarly, the computer generated validation marks for PR and QRS intervals were also reviewed as described above. In some instances, not all ECG intervals from a given ECG complex could be measured. For example, at rest and during the isoproterenol response a T wave may have coincided with a preceding P wave, or there was ventricular depolarization without atrial depolarization (ectopic beat or premature ventricular contraction). If the T wave morphology was preserved and the end of the T wave could be identified, the QT interval was recorded, but the PR interval was not measured. Therefore, rather than exclude all interval measurements from that waveform, we included those measurements that were valid. In those cases, the number of data points that was incorporated in the analyses was not the same (varied as much as 7%) for QT, PR, and QRS but resided in the same sequence of beats.
The raw signals were reviewed continuously for the last 10 min of period 1 and throughout the remaining treatment periods, including the infusions of isoproterenol (periods 2-4) as shown in Fig. 1. The TQ interval of the ECG was calculated as the RR interval minus the QT interval of the previous beat. The replayed data files containing the ECG intervals and BP measurements were imported into Excel (Microsoft, Redmond, WA) and transformed into a format that was read by programs written in MATLAB (Mathworks Inc., Natick, MA) and R (Ihaka and Gentleman, 1996
).
Statistical Analysis. The experiment was designed as a randomized block study with dog as the random block. Figure 1 shows the data analyses periods. Data from each period were broken down into two separate data sets for analyses: before isoproterenol (A) and during isoproterenol (B).
To examine changes in BP and ECG intervals, data were collected from each dog for a 10-min baseline period before initial treatment (period 1A) and for 5 min during the maintenance dose of each treatment (periods 2A, 3A, and 4A). The change in QT interval from baseline period 1A was estimated using the heart rate-adjusted bootstrap method. The method discussed in our previous work (Fossa et al., 2005
) estimated an uncorrected change in QT intervals from sequential sets of beat-to-beat ECG cycles. This value was adjusted for heart rate by estimating the distance to a typical baseline QT value within a similar 50-ms RR bin. The bootstrap technique was used to estimate the center of the distances because distribution of these distances does not resemble a standard normal distribution.
To examine the changes in hysteresis under delayed repolarization, data were collected for a maximum of 5 min after administration of the isoproterenol challenge. A baseline isoproterenol response before treatment was obtained (period 1B) and compared with isoproterenol responses after treatments (periods 2B, 3B, and 4B). These data were separated into an acceleration and deceleration phase by fitting a segmented regression function to RR interval versus time (sequential cardiac cycles). To assess the arrhythmia liability related to a diminishing diastolic interval, the minimum TQ value observed after isoproterenol challenge was used. Although the minimum is not considered a robust statistic, the data from this experiment suggested that the lower TQ bound was well defined and reliable, especially since the data were verified by manual over-reading.
The measure of heterogeneity used in the analyses was the area between the upper and lower 98% confidence bounds of the QT intervals across a specified TQ interval range. This calculation represents the average length of the QT confidence bounds, which is a standard measure of variability. The upper confidence bounds of the data were estimated by binning the TQ interval and fitting a spline through the 98% QT quantiles in each TQ bin (similarly for the lower confidence bounds). Analyses of data at rest before isoproterenol (A) encompassed all TQ intervals. Analyses of data during isoproterenol (B) used all beats occurring within the 98% QT interval confidence bounds below TQ intervals of 1000 ms to calculate total area of temporal heterogeneity. The total area of the heterogeneity for hysteresis was further broken down and standardized for dogs with different rates by using beats occurring during the time frame when TQ intervals were reducing from 1000 to 150 ms (acceleration) and increasing after peak response from 150 to 1000 ms (deceleration). To determine which variables differed significantly from baseline (period 1A or 1B) and time-matched vehicle (periods 2-4, A or B), the data from each data set were fit to a mixed effects repeated measures model in SAS version 8.2 (SAS Institute, Cary, NC).
| Results |
|---|
|
|
|---|
Representative examples of the beat-to-beat relationships between QT-RR and QT-TQ intervals (restitution) are illustrated in Fig. 2. The QT-RR interval and QT-TQ interval relationships seem very similar under normal conditions. However, as QT varies more with impaired repolarization, the restitution becomes more perturbed because changes in TQ interval take into account the increased short-long variability of QT interval also occurring on the adjacent cardiac cycle. By fixing TQ interval on the horizontal axis (restitution panel), assessing where the diastolic period approaches zero for individual cardiac cycles is more apparent than when plotted on the QT-RR axes (see diagonal line where TQ = 0 when RR = QT). Restitution responses to all treatments in the same dog are illustrated in Fig. 3.
|
|
|
L-768,673 significantly increased QT interval 27 ms during period 2A compared with baseline (period 1A). This was accompanied by a reduction of the TQ interval of 26 ms. These changes, however, did not remain constant throughout the study despite a reported duration of activity for L-768,673 of greater than 15 h (Salata et al., 2004
; also see Discussion). For periods 3A and 4A, the QT interval only increased 11 and 6 ms, respectively, both of which were not statistically different from controls (period 1A for L-768,673 and periods 3A and 4A for vehicle). RR interval and heterogeneity showed no differences during any period with L-768,673.
E-4031 caused dose-dependent increases in QT and reductions in TQ intervals with no changes in RR interval. The respective QT and TQ interval changes were statistically significant at period 3A (17 and -18 ms) and period 4A (24 and -28 ms). No statistically significant effect on heterogeneity was observed.
The combination of IKs and IKr inhibition with L-768,673 + E-4031 produced statistically significant increases in QT interval and decreases in TQ interval at all dose levels (see example in Fig. 3). The largest changes in QT (+50 ms) and TQ (-46 ms) intervals occurred during period 2A but remained approximately 38 ms for QT and -41 ms for TQ during periods 3A and 4A. No changes in RR interval were observed during any period. Heterogeneity was increased approximately 47 to 79% during periods 2A, 3A, and 4A compared both with baseline (period 1A) and 55 to 91% compared with the time-matched vehicle responses. Compared with responses of L-768,673 and E-4031 alone, it would seem that the magnitude of the effects on QT, TQ, and particularly heterogeneity are more than additive with the combination [i.e., period 4A heterogeneity; L-768,673 (-2718 ms2) + E-4031 (492 ms2) < 15352 ms2 with combination].
Since the QT-TQ interval relationship was most affected during the combination of E-4031 and L-768,673, the effect on conduction velocity was assessed as well. The combination produced no changes in either PR or QRS intervals during period 4A compared with baseline (period 1A) or the time-matched vehicle control response during period 4A (Table 1).
Effect of Isoproterenol on Restitution Hysteresis (Heterogeneity and Minimum TQ Analyses) before and after Impaired Repolarization (Periods 1B, 2B, 3B, and 4B)
The changes in hysteresis as measured by heterogeneity of the plotted temporal response during acceleration, deceleration, and total response as well as minimum TQ interval with isoproterenol challenges are represented in Table 2. As expected, isoproterenol reduced BP and PR interval while increasing heart rate (as RR interval); these parameters were not statistically assessed across treatments. Figure 4 illustrates the response to isoproterenol and how heterogeneity was calculated for each phase in a representative single animal. Also see a supplemental dynamic beat-to-beat movie of the data within Fig. 4 (supplemental data, IKs+IKr block with iso.avi).
|
|
Total Heterogeneity. Significant increases in total heterogeneity of 25% were obtained with L-768,673 in period 2B and with E-4031 (30 and 53%) in periods 3B and 4B, respectively, compared with pretreatment baseline responses to isoproterenol (period 1B). The combination of L-768,673 + E-4031 increased total heterogeneity during all three treatment periods between 41 and 89%. These data seem to indicate that total heterogeneity follows closely the magnitude of the effect on the resting TQ interval (Table 1).
Acceleration Phase. No changes were observed in acceleration heterogeneity after L-768,673 or E-4031 alone (TQ interval reducing from 1000 to 150 ms). The combination L-768,673 + E-4031 statistically increased acceleration heterogeneity 41% during period 3B and 57% during period 4B.
Deceleration Phase. No statistically significant changes were observed with vehicle or treatment during the deceleration phase after isoproterenol for any period. From this information, it would seem that changes in total heterogeneity after impaired repolarization were determined primarily by changes in acceleration heterogeneity only. It should be mentioned here, although not noted in Table 2, analyses of the isoproterenol responses at each period after saline showed statistically significant decreases in the total heterogeneity at each period, indicating that some attenuation of the isoproterenol response occurred across all groups with time.
TQ Minimum. As TQ approaches zero, theoretically, arrhythmia liability will increase and thus the minimum TQ interval was examined. No significant effects on minimum TQ were observed with L-768,673 or E-4031 alone. A statistically significant decrease to a mere 28 ms was observed only with the combination L-768,673 + E-4031 during period 4B. This decrease of 73 ms represented a 72% change from the period 1B baseline response.
| Discussion |
|---|
|
|
|---|
Treatment with the selective IKr blocker E-4031 produced a dose-related prolongation in the QT interval consistent with previous studies (Fossa et al., 2002
). Selective blockade of IKs current with L-768,673, in contrast, produced a much larger increase in the QT interval upon initial dosing during period 2A, but it attenuated during periods 3A and 4A. This effect that diminished with time may have resulted from additional nonselective IKr block reported for L-768,673 by Salata et al. (2004
) with high concentrations that were most likely achieved upon initial i.v. dosing before complete drug distribution. It should be noted that upon initial dosing, QT prolongation of greater than 70 ms was observed in all dogs, and as much as 120 ms for some, without incidence of arrhythmia (data not shown). Humans, in contrast, may not be able to tolerate such changes without producing arrhythmia for the reasons discussed below.
The combination of IKr and IKs inhibition with E-4031 + L-768,673 produced greater QT prolongation than the apparent additive responses to the individual agents. This effect could not be attributed to any changes in conduction velocity as measured by the PR and QRS intervals. Thus, it is most likely attributed to more complete inhibition of the repolarization reserve as described by Roden (1998
). Isoproterenol challenge during combined IKr and IKs inhibition caused a marked increase in hysteresis primarily due to increased heterogeneity of the cardiac cycles upon acceleration. Since isoproterenol increases cardiac intracellular calcium release through
-adrenergic stimulation (Steinberg et al., 2002
), it is speculated that a lack of repolarization capacity amplifies the heterogeneity (O'Rourke et al., 1999
; Katra et al., 2004
). QT interval at rest was ominously increased with decreasing TQ (Fig. 3), and a transient sharp increase in QT variability (as evidenced by an increase QT width of cloud) was apparent in three of the five dogs at higher heart rates.
|
The ability of our model to assess arrhythmia liability is based on the restitution principal that each working cycle of the heart (QT interval) is determined partly by the preceding resting diastolic phase (TQ interval). To conceptualize this model, Fig. 5 is a hand-drawn cartoon to illustrate the impact of heart rate on the QT-TQ relationship with QT prolongation, and why it may be associated with ventricular arrhythmia. At a normal human resting heart rate of 60 bpm (RR interval = 1000; QT interval = 430 ms), the heart has roughly half the time between heart beats (RR-QT = TQ of 570 ms) to get its nutrients and for the ionic kinetics of each cell to return to steady state. QT interval decreases with increasing heart rate (Fridericia, 1920
) so that on average for a heart rate of 150 bpm, the QT interval would be 320 ms. TQ interval is reduced at this rate 7-fold to 80 ms. Coincidentally, it is generally regarded that healthy humans transition from ventricular tachycardia to fibrillation at around 250 bpm (where TQ = zero when RR = QT). Torsades de Pointes arrhythmia theoretically could be caused by conduction block in the same way when heart rate is accelerated to the point where TQ approaches zero (i.e., RR = QT) as well. QT prolongation may be associated with Torsades de Pointes because as the QT interval is prolonged at high heart rates, a disproportionate amount of the TQ interval is reduced. TQ interval is reduced from 570 ms at rest to 10 ms with prolongation and tachycardia (e.g., a 57-fold reduction in TQ versus a 20% increase in QT interval), thus providing much less time for the heart to recover between beats. Concurrent with the reduction of the diastolic interval, it has been demonstrated that accumulation of intracellular calcium occurs that is associated with the generation of alternans (a measure of temporal heterogeneity; Chudin et al., 1999
). This may lead to increases in spatial heterogeneity (Katra et al., 2004
) and triggering of arrhythmias (Karma, 1994
). Luo-Rudy equations of ion kinetics would predict that this response would be further amplified with sudden changes from bradycardia or a long pause (Viswanathan and Rudy, 1999
).
Generation of arrhythmias to confirm the relationship of biomarkers such as heterogeneity and TQ minimum to outcome may be more difficult in dogs than in humans. Dogs have a profound sinus arrhythmia as part of their normal cardiac physiology (Hariman et al., 1980
) that is compensated by ionic mechanisms that may adapt more quickly to heart rate changes than humans. Interestingly, even though the resting heart rate of the dog and human is almost the same (i.e., 60 bpm), the average dog QT interval (240 ms) is approximately 200 ms shorter than humans at the same heart rate. This may allow an additional 200 ms during heart rate acceleration or QT interval prolongation for the TQ interval to provide recovery of the heart between beats. This could explain why we did not observe arrhythmias in our study even when transient increases of >100 ms of the QT interval were obtained with the combination of L-768,673 + E-4031.
The choice for autonomic challenge, in our case isoproterenol (1-min infusion), is very important for determining the analysis range and the hysteresis profile. Unlike humans, the sinus arrhythmia in dogs causes RR intervals to oscillate between approximately 400 and 1600 ms with every respiratory cycle at rest. To standardize the heterogeneity boundary during acceleration and deceleration, TQ intervals above 1000 ms were omitted from the analyses even though they temporally occurred with isoproterenol when the sinus arrhythmia was maintained early in the infusion. Likewise, at very fast heart rates individual beats oscillated below TQ values of 150 ms, making the true nadir of the response difficult to determine. Even though humans exhibit much less sinus arrhythmia, the rapidity and direction of the RR or TQ interval change will always need to be considered in the analyses. TQ interval is not equivalent to RR interval and thus should not be extrapolated to mean heart rates. TQ interval takes into account the high short-long variability of QT interval also occurring on the adjacent cardiac cycle. To visualize the sequential beat-to-beat dynamics during heart rate changes, a supplemental movie of the response has been appended (see supplemental data, IKs+IKr block with iso.avi).
Limitations of Study. We did not compare our restitution findings to direct measurements of APD/DI. Although this would be of interest in future studies, we would expect differences. Regional events (e.g., apical versus basal; left ventricular versus right ventricular, endocardial versus epicardial) may not be recognized by the ECG restitution because it represents a summation of electrical activity. Systematic study will probably be required to determine which cardiac region best coincides with surface measurements. Technically, computerized data acquisition systems for digital analyses of large volumes of high-quality digital ECG data are in their early stages of development. Only recently has it been possible to begin quantitative assessment of the sequential beat-to-beat dynamics (Jensen et al., 2004
; Fossa et al., 2005
; Mizumaki et al., 2005
). Many issues with automated systems affecting spatial differences and T wave morphology must be overcome to improve confidence it their use without manual oversight of all beats.
In conclusion, using dynamic beat-to-beat analyses, these parameters and hopefully others may be measured in the conscious normal autonomic state and could lead to noninvasive biomarkers for assessment of changes associated with arrhythmogenic risk. However, since arrhythmia was not produced with the treatments in this study, it cannot be determined which of the parameters best describes the absolute risk. Ethically, this will only be verifiable with these analyses in the normal conscious state when performed retrospectively with human Holter-acquired data where arrhythmias occurred.
| Acknowledgements |
|---|
| Footnotes |
|---|
ABBREVIATIONS: DI, diastolic interval; APD, action potential duration; LQT, long QT syndrome; L-768,673, (R)-2-(4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide; E-4031, (1-[2-(6-methyl-2-pyridyl)ethyl]-4-methyl-sulfonylaminobenzoyl)-piperidine; BP, blood pressure; bpm, beats per minute.
The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material. ![]()
Address correspondence to: Dr. Anthony A. Fossa, Pfizer Global Research and Development, Eastern Point Rd., Bldg. 118E, MS 4036, Groton, CT 06340. E-mail: anthony.a.fossa{at}pfizer.com
| References |
|---|
|
|
|---|
Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding D-W, Zankov DP, Toyoda F, Matsuura H, Horie M, et al. (2005) Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 45: 300-307.
Bass BG (1975) Restitution of the action potential in cat papillary muscle. Am J Physiol 228: 1717-1724.
Chudin E, Goldhaber J, Garfinkel A, Weiss J, and Kogan B (1999) Intracellular Ca2+ dynamics and the stability of ventricular tachycardia. Biophys J 77: 2930-2941.[Medline]
Fossa AA, DePasquale MJ, Raunig DL, Avery MJ, and Leishman DJ (2002) The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J Pharmacol Exp Ther 202: 828-833.[CrossRef]
Fossa AA, Wisialowski T, Magnano A, Wolfgang E, Winslow R, Gorczyca W, Crimin K, and Raunig DL (2005) Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether-a-go-go-related gene inhibition. J Pharmacol Exp Ther 312: 1-11.
Fox JJ, McHarg JL, and Gilmour RF Jr (2002) Ionic mechanism of electrical alternans. Am J Physiol 282: H516-H530.
Fridericia LS (1920) Systolendauer im elecktrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 53: 469-486.
Fujiki A, Tani M, Mizumaki K, Shimono M, and Inoue H (1994) Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 23: 374-378.[Medline]
Gilmour RF Jr, Riccio ML, Locati EH, Maison-Blanche P, Coumel P, and Schwartz PJ (1997) Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation. J Am Coll Cardiol 30: 209-217.[Abstract]
Hariman RJ, Hoffman BF, and Naylor RE (1980) Electrical activity from the sinus region in conscious dogs. Circ Res 47: 775-791.
Hondeghem LM, Carlsson L, and Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
Ihaka R and Gentleman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5: 299-314.[CrossRef]
Jensen BT, Larroude CE, Rasmussen LP Holstein-Rathlou N-H, Hojgaard MV, Agner E, and Kanters JK (2004) Beat-to-beat QT dynamics in healthy subjects. Ann Noninvasive Electrocardiol 9: 3-11.[CrossRef][Medline]
Kalb SS, Dobrovolny HM, Tolkacheva EG, Idriss SF, Krassowska W, and Gauthier DJ (2004) The restitution portrait: a new method for investigating rate-dependent restitution. J Cardiovasc Electrophysiol 15: 698-709.[CrossRef][Medline]
Karagueuzian HS and Chen PS (1999) Graded response and restitution hypotheses of ventricular vulnerability to fibrillation: insights into the mechanism of initiation of fibrillation. J Electrocardiol 32: S87-S91.[CrossRef]
Karma A (1994) Electrical alternans and spiral wave break-up in cardiac tissue. Chaos 4: 461-472.[CrossRef][Medline]
Katra RP, Pruvot E, and Laurita KE (2004) Intracellular calcium handling heterogeneities in intact guinea pig hearts. Am J Physiol 286: H648-H656.
Krahn AD, Yee R, Chauhan V, Skanes AC, Wang J, Hegele RA, and Klein GJ (2002) Beta blockers normalize QT hysteresis in long QT syndrome. Am Heart J 143: 528-534.[CrossRef][Medline]
Mizumaki K, Fujiki A, Sakabe M, Nishida K, Sugao M, Tsuneda T, Nagasawa H, and Inoue H (2005) Dynamic changes in the QT-RR relationship during head-up tilt test in patients with vasovagal syncope. Ann Noninvasive Electrocardiol 10: 16-24.[Medline]
O'Rourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, and Marban E (1999) Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure I: experimental studies. Circ Res 84: 562-570.
Otani N and Gilmour RF Jr (1997) Memory models for the electrical properties of local cardiac systems. J Theor Biol 187: 409-436.[CrossRef][Medline]
Pruvot EJ, Katra RP, Rosenbaum DS, and Laurita KR (2004) Role of calcium cycling versus restitution in the mechanism of repolarization alternans. Circ Res 94: 1083-1090.
Qu Z, Weiss JN, and Garfinkle A (1999) Cardiac electrical restitution properties and stability of reentrant spiral waves: a simulation study. Am J Physiol 276: H269-H283.
Raunig D, DePasquale MJ, Huang C-H, Winslow R, and Fossa AA (2001) Statistical analysis of QT interval as a function of changes in RR interval in the conscious dog. J Pharmacol Toxicol Methods 46: 1-11.[CrossRef][Medline]
Roden DM (1998) Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. PACE 21: 1029-1034.
Salata JJ, Selnick HG, and Lynch JJ Jr (2004) Pharmacological modulation of IKs: potential for antiarrhythmic therapy. Curr Med Chem 11: 29-44.[CrossRef][Medline]
Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, et al. (2001) Genotype-phenotype correlation in the long-QT syndrome gene-specific triggers for life-threatening arrhythmias. Circulation 103: 89-95.
Shimizu W and Antzelevitch C (1998) Cellular basis for the ECG features of the LQT1 form of the Long-QT syndrome: effects of the
-adrenergic agonist and antagonist and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 98: 2314-2322.
Steinberg SF, Alcott S, Pak E, Hu D, Protas L, Moise NS, Robinson RB, and Rosen MR (2002) (beta)1-Receptors increase cAMP and induce abnormal Ca(i) cycling in the German shepherd sudden death model. Am J Physiol 282: H1181-H1188.
Thomsen MB, Truin M, van Opstal JM, Beekman JDM, Volders PGA, Stengl M, and Vos MA (2005) Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res Cardiol 100: 279-287.[CrossRef][Medline]
Thomsen MB, Verduyn SC, Stengl M, Beekman JDM, de Pater G, van Opstal J, Volders PGA, and Vos MA (2004) Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110: 2453-2459.
Viswanathan PC and Rudy Y (1999) Pause induced early afterdepolarization in the long QT syndrome: a simulation study. Cardiovasc Res 42: 530-542.
Volders PG, Stengl M, van Opstal JM, Gerlach U, Spatjens RL, Beekman JD, Sipido KR, and Vos MA (2003) Probing the contribution of IKs to canine ventricular repolarization: key role for
-adrenergic receptor stimulation. Circulation 107: 2753-2760.
This article has been cited by other articles:
![]() |
M. Sala, M. Lazzaretti, G. De Vidovich, E. Caverzasi, F. Barale, G. d'Allio, and P. Brambilla Electrophysiological changes of cardiac function during antidepressant treatment Therapeutic Advances in Cardiovascular Disease, February 1, 2009; 3(1): 29 - 43. [Abstract] [PDF] |
||||
![]() |
E. Pueyo, J. P. Martinez, and P. Laguna Cardiac repolarization analysis using the surface electrocardiogram Phil Trans R Soc A, January 28, 2009; 367(1887): 213 - 233. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||